Modality
ASO
MOA
JAK1/2i
Target
FcRn
Pathway
Hedgehog
CRC
Development Pipeline
Preclinical
~May 2016
→ ~Aug 2017
Phase 1
Nov 2017
Phase 1Current
NCT05103753
1,047 pts·CRC
2017-11→TBD·Active
NCT07889929
962 pts·CRC
2022-01→TBD·Not yet recruiting
2,009 total pts1 indication
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Trial Timeline
2018Q2Q3Q42019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022
P1/2
Active
P1/2
Not yet…
ActiveNot yet recruiting|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT05103753 | Phase 1/2 | CRC | Active | 1047 | Mayo |
| NCT07889929 | Phase 1/2 | CRC | Not yet recr... | 962 | SRI-4 |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| Cevizanubrutinib | Johnson & Johnson | Preclinical | FcRn | |
| Gelinaritide | AbbVie | Preclinical | FcRn | |
| Fixanesiran | AbbVie | Preclinical | RET | |
| Motavorutinib | Amgen | Phase 3 | CDK4/6 | |
| Talalemzoparlimab | Gilead Sciences | Phase 1 | FcRn | |
| VRT-9481 | Vertex Pharma | Phase 1/2 | Menin | |
| Sovafutibatinib | Moderna | Approved | FcRn | |
| Sovarelsin | BioMarin | Phase 2 | CFTR | |
| Peminaritide | Sarepta | NDA/BLA | PLK4 | |
| ITC-879 | Intra-Cellular | Approved | FcRn |